Eli Lilly Receives FDA Endorsement for Retevmo
Eli Lilly and Company (LLY) announced that the FDA has granted its approval for Retevmo, making it the first approved therapy specifically targeting adult patients with metastatic rearranged during transfection ((RET)) fusion-positive non-small cell lung cancer. The therapy also has the approval for treating adult and pediatric patients 12 years of age and older suffering from advanced or metastatic RET-mutant medullary thyroid cancer ((MTC)) needing systemic therapy.
Retevmo is a selective RET kinase inhibitor and may impact both the healthy cells as well as tumor cells. This oral